Pharma major Lupin on Monday said it has launched its Sildenafil tablets used for the treatment of erectile dysfunction in the US market.
The company has launched Sildenafil tablets USP in the strengths of 25 mg, 50 mg and 100 mg after receiving approval from the United States Food and Drug Administration (USFDA) earlier, Lupin said in a filing to the BSE.
The company's product is the generic version of Pfizer Inc's Viagra tablets in the same strengths, it added.
As per IQVIA MAT July 2019 data, Sildenafil tablets USP, 25 mg, 50 mg, and 100 mg had total annual sales of around USD 216 million in the US, Lupin said.
Sildenafil tablets are indicated for the treatment of erectile dysfunction, it added.
Shares of Lupin Ltd on Monday closed at Rs 715.85 per scrip on the BSE, down 0.09 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app